Skip to main content
NCBI home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 1998 Dec 12;12(6):356–362. doi: 10.1002/(SICI)1098-2825(1998)12:6<356::AID-JCLA5>3.0.CO;2-#

Determination of the bioavailability of intranasal elcatonin in humans: Development of a sandwich transfer enzyme immunoassay for elcatonin

Takeyuki Kohno 1,✉, Noriaki Murasugi 1, Hiroki Sakurai 1, Kazuhito Watabe 1, Hiromichi Nakamuta 2, Masao Koida 2, Yohko Sugie 3,4, Toshiyo Ogouchi 5, Tadashi Inoue 5, Masao Yanaka 5, Masakatsu Nomura 6, Akira Yanagawa 6
PMCID: PMC6808144  PMID: 9850187

Abstract

A sandwich transfer enzyme immunoassay for elcatonin (ECT) and its usability for the pharmacokinetic study are described. The anti‐salmon calcitonin (SCT) antibody was used for the present assay. The assay procedure consisted of the reaction of ECT with 2,4‐dinitrophenylbiotinyl anti‐SCT IgG and anti‐SCT Fab′‐β‐d‐galactosidase conjugate, trapping onto (anti‐2,4‐dinitrophenyl bovine serum albumin) IgG‐coated polystyrene balls, eluting with ϵN‐2,4‐dinitrophenyl‐L‐lysine and transferring to streptavidin‐coated polystyrene balls and fluorometric detection of β‐d‐galactosidase activity. The practical detection limit of ECT was 0.15 pg (44 amol)/50 μl of sample and 3 pg/ml as the concentration. The application of this method has enabled us to directly estimate the bioavailability of ECT dosed intranasaly at a therapeutic level (100 IU, 17 μg) for its anti‐osteoporotic effect as compared to an intramuscular dose (40 IU, 6.7 μg). The pharmacokinetic parameters of the intranasal ECT (n = 6) thus estimated were as follows: the area under the serum concentration‐time curve (AUC) = 2,570 ± 1,650 (SD) pg × min/ml, and the maximal concentration (Cmax) = 60 ± 25 (SD) pg/ml with the maximal time (Tmax) = 17.5 ± 6.9 (SD) min, when the AUC for the intramuscular ECT (n = 9) = 9,460 ± 5,870 (SD) pg × min/ml and the Cmax = 165 ± 79 (SD) pg/ml with the Tmax = 16.1 ± 4.2 (SD) min. J. Clin. Lab. Anal. 12:356–362, 1998. © 1998 Wiley‐Liss, Inc.

Keywords: pharmacokinetics, osteoporosis, osteomalacia, thyroid, hormone

References

  • 1. Chambers TJ, Magnus CJ: Calcitonin alters behavior of isolated osteoclasts. J Pathol 136: 27–39, 1982. [DOI] [PubMed] [Google Scholar]
  • 2. Murrills RJ, Shane E, Lindsay R, Dempster DW: Bone resorption by isolated human osteoclasts in vitro: Effects of calcitonin. J Bone Miner Res 4: 259–268, 1989. [DOI] [PubMed] [Google Scholar]
  • 3. Nicholson GC, Moseley JM, Sexton PM, Mendelsohn FAO, Martin TJ: Abundant calcitonin receptors in isolated rat osteoclasts. J Clin Invest 78: 355–360, 1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Azria M: The Calcitonins: Physiology and Pharmacology. Karger, Basel, 1989. [Google Scholar]
  • 5. Morikawa T, Munekata E, Sakakibara S, Noda T, Otani M: Synthesis of eel‐calcitonin and Asul, 7‐eel‐calcitonin: Contribution of the disulfide bond to the hormonal activity. Experientia 32: 1104–1106, 1976. [DOI] [PubMed] [Google Scholar]
  • 6. Kohno T, Nakamuta H, Ichikawa M, Watabe K, Koida M: A noncompetitive enzyme immunoassay (hetero‐two‐site enzyme immunoassay) for salmon calcitonin: Determination of the bioavailability of subcutaneous salmon calcitonin and its correlation with the hypocalcemic activity in rats. J Clin Lab Anal 10: 91–97, 1996. [DOI] [PubMed] [Google Scholar]
  • 7. Nakamuta H, Kohno T, Ichikawa M, Hoshino T, Watabe K, Koida M: Plasma level monitoring of nasal salmon calcitonin in the rats by a heterogeneous two‐site enzyme immunoassay. J Clin Lab Anal 11: 129–131, 1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Kohno T, Murasugi N, Sakurai H, et al.: A sandwich transfer enzyme immunoassay for salmon calcitonin: Determination of the bioavailability of intranasal salmon calcitonin in human. J Clin Lab Anal 11: 380–387, 1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Nogata Y, Yamamoto Y, Sakurada T, et al.: Physico‐chemical properties and assay of elcatonin. Iyakuhin Kenkyu 13: 334–339, 1982. [Google Scholar]
  • 10. Kimura T, Kiso Y: Results of chemical analysis of commercially available elcatonin preparation. Clin Rep 29: 1626–1630, 1995. [Google Scholar]
  • 11. Sieber P, Brugger M, Kamber B, Riniker B, Rittel W: Human calcitonin. IV. Synthesis of calcitonin M. Helv Chim Acta 51: 2057–2061, 1968. [DOI] [PubMed] [Google Scholar]
  • 12. Hashida S, Ishikawa E: Detection of one milliatto mole of ferritin by novel and ultrasensitive enzyme immunoassay. J Biochem 108: 960–964, 1990. [DOI] [PubMed] [Google Scholar]
  • 13. Kohno T, Kitamura T, Tsuda K, Ishikawa E: Novel and sensitive enzyme immunoassay (immune‐complex‐transfer enzyme immunoassay) for alpha‐fetoprotein from hepatocellular carcinoma. J Clin Lab Anal 4: 183–188, 1990. [DOI] [PubMed] [Google Scholar]
  • 14. Kohno T, Ishikawa E, Sugiyama S, Nakamura S: Novel enzyme immunoassay of anti‐insulin IgG in human serum. J Clin Lab Anal 2: 19–24, 1988. [Google Scholar]
  • 15. Ishikawa E, Imagawa M, Hashida S, Yoshitake S, Hamaguchi Y, Ueno T: Enzyme‐labeling of antibodies and their fragments for enzyme immunoassay and immunohistochemical staining. J Immunoassay 4: 209–327, 1983. [DOI] [PubMed] [Google Scholar]
  • 16. Kohno T, Ishikawa E: A highly sensitive enzyme immunoassay of antiinsulin antibodies in guinea pig serum. J Biochem 100: 1247–1251, 1986. [DOI] [PubMed] [Google Scholar]
  • 17. Inoue S, Hashida S, Kohno T, Tanaka K, Ishikawa E: A micro‐scale method for the conjugation of affinity‐purified Fab′ to β2‐D‐galactosidase from Escherichia coli. J Biochem 98: 1387–1394, 1985. [DOI] [PubMed] [Google Scholar]
  • 18. Ishikawa E, Kato K: Ultrasensitive enzyme immunoassay. Scand J Immunol 8 (suppl.7): 43–55, 1978. [Google Scholar]
  • 19. Tanaka K, Hashida S, Kohno T, Yamaguchi K, Ishikawa E: Novel and sensitive noncompetitive enzyme immunoassay to measure peptides by biotinylation. Anal Lett 22: 353–363, 1989. [Google Scholar]
  • 20. Imagawa M, Hashida S, Ishikawa E, et al.: A highly sensitive sandwich enzyme immunoassay for insulin in human serum developed using capybara anti‐insulin Fab′‐horseradish peroxidase conjugate. Anal Lett 16: 1509–1523, 1983. [Google Scholar]
  • 21. Yamaoka K, Nakagawa T, Uno T: Statistical moments in pharmacokinetics. J Pharmacoldn Biopharm 6: 547–558, 1978. [DOI] [PubMed] [Google Scholar]
  • 22. Riegelman S, Collier P: The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacoldn Biopharm 8: 509–534, 1980. [DOI] [PubMed] [Google Scholar]
  • 23. Akikawa R, Ohyama K, Mori E, Hironaka K, Miyake M, Morishita M: Enzyme immunoassay for elcatonin, a synthetic analogue of eel calcitonin, in plasma. J Pharm Sci 74: 300–303, 1985. [DOI] [PubMed] [Google Scholar]
  • 24. Takayama M, Ikawa K, Eto I, Mori K: Enzyme immunoassay of elcatoninin human plasma. Biol Pharm Bull 18: 900–902, 1995. [DOI] [PubMed] [Google Scholar]
  • 25. Fenton AJ, Martin TJ, Nicholson T: Long‐term culture of disaggregated rat osteoclast: Inhibition of bone resorption and reduction of osteoclastlike cell number by calcitonin and PTHrP (107–139). J Cell Physiol 155: 1–7, 1993. [DOI] [PubMed] [Google Scholar]
  • 26. Hoshino T, Nakamuta H, Ichikawa M, Koida M: Influence of osteostain on osteoclast morphology. Jpn J Pharmacol 64 (Suppl. I): 289P, 1994. 8057530 [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES